IN RE SOLODYN (MINOCYCLINE HYDROCHLORIDE) ANTITRUST LITIGATION

MDL No. 2503
1:14-md-2503-DJC

If you purchased brand or generic Solodyn (extended-release minocycline hydrochloride tablets) directly from Medicis Pharmaceutical Corp., Impax Laboratories, Inc., and/or other manufacturers, a class action lawsuit could affect your rights.

Important Dates

January 25, 2018 - Deadline to Postmark Requests for Exclusion

March 12, 2018 - Trial Commencement

Ahold USA, Inc. and Rochester Drug Co-Operative, Inc. (“Plaintiffs”) have sued defendants (a) Medicis Pharmaceutical Corp. (“Medicis”), (b) Impax Laboratories, Inc. (“Impax”), (c) Sandoz Inc. (“Sandoz”), and (d) Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”) (collectively, “Defendants”). The Plaintiffs allege that the Defendants violated federal antitrust laws by unlawfully impairing the introduction of generic versions of the prescription drug Solodyn into the United States market. The Plaintiffs allege that Medicis entered into an illegal reverse payment agreement with Impax that impaired generic Solodyn competition. The lawsuit claims this reverse payment agreement injured Plaintiffs and members of a class of direct purchasers of brand and generic Solodyn by causing them to pay higher prices for extended-release minocycline hydrochloride tablets. Medicis and Impax deny these claims and deny that they did anything wrong.

Plaintiffs previously settled their claims with Sandoz and Lupin. More information about the settlements with Sandoz and Lupin is available at www.SolodynDirectPurchaserAntitrustLitigation.com. You may have received a notice concerning those settlements on or after April 28, 2017.

The case against Medicis and Impax is still ongoing. On October 16, 2017, Judge Denise J. Casper of the United States District Court for the District of Massachusetts allowed this antitrust lawsuit to proceed as a class action, and certified the following class:

All persons or entities in the United States and its territories, including Puerto Rico, who purchased (a) 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg brand or generic Solodyn tablets directly from any Defendant or other manufacturer at any time during the period July 23, 2009 through and including November 25, 2012 and/or (b) 55mg, 65mg, 80mg, 105mg, and/or 115mg brand Solodyn tablets directly from Medicis at any time from November 26, 2012 until November 30, 2015. Excluded from the Class are Defendants, and their officers, directors, management, employees, subsidiaries, or affiliates, and all federal governmental entities.

Summary Of Your Options And Legal Rights In This Settlement

DO NOTHING

By doing nothing, and if you are a member of the class, then you will remain in the class and may be entitled to share in any recovery that may come from a trial or settlement with Medicis and Impax. All of the Court’s orders will apply to you and legally bind you.

EXCLUDE YOURSELF FROM THE CLASS

This is the only option that allows you to file or be part of another lawsuit against Defendants Medicis and Impax relating to the claims in this case. If you exclude yourself from the class, you will not be bound by any of the Court’s orders in this case as to the claims against Medicis and Impax, nor will you be entitled to participate in and benefit from any recovery in this case.

Click here to learn more about excluding yourself from the class.

GET MORE INFORMATION

If you would like more information about the lawsuit, you can review the Notice and send questions to the lawyers identified in Question 11.


THESE RIGHTS AND OPTIONS
– AND THE DEADLINES TO EXERCISE THEM –
ARE EXPLAINED IN THE NOTICE.

Copyright © 2017
Privacy Policy